PuraMed BioScience Completes Distribution Agreement with FastFunds Financial Corporation for Its Migraine Relief Product

SCHOFIELD, Wis., Dec. 9, 2014 /PRNewswire/ -- PuraMed BioScience^®, Inc., (OTC Pink: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it has entered into a 5-year distribution agreement with FastFunds Financial Corporation (OTC Pink: FFFC) of West Palm Beach, Florida for distribution of MigraPure^® H, a hemp-based, advanced migraine relief product.

"We are pleased to have entered into an agreement with PuraMed BioScience," said Henry Fong, chairman and CEO of FastFunds Financial Corporation. "PuraMed's MigraPure H migraine product is a good fit with our company's mission to fund early-stage cannabis projects. We look forward to a productive and profitable relationship for both companies as the product is launched and more are developed."

The agreement gives FastFunds Financial Corporation exclusive distribution rights in the marijuana market segment in the United States. This segment includes all 50 states, but only applies to legally permitted: medical marijuana dispensaries, recreational marijuana retail stores, online retailers who sell primarily marijuana and hemp products and accessories, and other establishments with the primary business of selling medical and/or recreational marijuana and related accessories. FastFunds plans to market the MigraPure^® H product through its 49 percent equity ownership in WMII, Inc. and their accessibility to a database of 1,000 medical and recreational marijuana dispensaries in Colorado, Washington State, and California.

"This is a great opportunity for us," said Russell Mitchell, CEO of PuraMed BioScience. "The agreement gives people access to our products in more than 1,000 dispensaries and other distribution venues throughout Colorado, Washington State, and California. We will be selling MigraPure H^®, our hemp-based headache formulation at these venues. We hope to have the product on shelves early in 2015.

"In addition to MigraPure H, we also see potential in this market segment for several other products and technologies we are investigating. We have begun viability testing with several of the most promising."

Preliminary findings of domestic studies show cannabinoids relieve anxiety, post-traumatic stress disorder (PTSD), and epilepsy symptoms. Several international studies have shown cannabinoids can reduce cancer pain, minimize multiple sclerosis symptoms, and have a positive impact on other disease states.

"MigraPure H allows us to make our entrance into the cannabis space with our hemp-based homeopathic advanced headache product," said Mitchell. "As we promote our existing products, we will continue to focus on the research and development of multiple products containing hemp to treat neurologic and biologic disorders within the over-the-counter, health and wellness category."

About MigraPure^® and MigraPure^® H
MigraPure Advanced Migraine Relief is a sublingual feverfew and ginger gel that was clinically tested under the name LipiGesic^® M. The peppermint flavor of this homeopathic, all-natural, over-the-counter migraine headache pain reliever has been enhanced, but the clinically tested active ingredients remain the same.

MigraPure stops disabling migraine pain and associated symptoms quickly. Its patented sublingual (under-the-tongue) delivery system efficiently delivers the active ingredients directly into the bloodstream for fast relief. By avoiding the liver and stomach, MigraPure's maximum strength ingredients work faster and more effectively than traditional pills or capsules.

MigraPure's feverfew and ginger gel is non-drowsy, non-habit forming, and not associated with rebound headaches. MigraPure has an excellent safety profile with no reported drug interactions.

MigraPure H Advanced Headache Relief is PuraMed's most recent all-natural, hemp-based headache reliever. The active ingredients in MigraPure have been combined with a hemp-base to create a powerful treatment for migraines and seizure-related headache. Early indications show the formulation may also be effective for tension and cluster headaches and other epilepsy symptoms.

MigraPure^® H does not violate any Federal laws pertaining to the cultivation, distribution or marketing of a controlled or banned substance.

About PuraMed BioScience, Inc.:
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products.

PuraMed BioScience also specializes in the development of sublingual homeopathic medications. This type of formulation delivers active ingredients directly into the blood stream for faster relief and greater effectiveness with fewer side effects than their chemical counterparts.

PuraMed BioScience believes in the value of clinical trials. The company's goal is to build medicines that can withstand scientific scrutiny and perform well in double-blind, placebo-controlled clinical trials. MigraPure, clinically tested as LipiGesic^®M, showed it was effective in the treatment of acute migraine in 64 percent of occurrences. The clinical trial results were published in the top-tier medical journal, Headache: The Journal of Head and Face Pain.

In addition to MigraPure and MigraPure H, PuraMed BioScience plans to launch additional cannabinoid-enhanced, anti-inflammatory, and anxiolytic products as it moves forward in the development of its cannabinoid product line.

About FastFunds Financial Corporation
FastFunds Financial Corporation ("FastFunds" or the "Company") is a holding company that is publicly traded on the OTC Pink exchange, under the symbol "FFFC". Through its wholly-owned subsidiaries, Cannabis Angel, Inc., and The 420 Development Corporation, the Company is focused on acquiring and building a portfolio of revenue producing companies that provide ancillary services to the cannabis industry.  FastFunds does not engage in activities that violate Federal laws.

Forward-Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
PuraMed BioScience, Inc.
Russ Mitchell
[email protected] 
Phone: 715.359.6373
www.PuraMedBioScience.com

For Additional Information Pertaining to FastFunds Financial Corporation:
FastFunds Financial Corporation
Mr. Henry Fong
President and Chief Executive Officer
Phone: 561.514.9042

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/puramed-bioscience-completes-distribution-agreement-with-fastfunds-financial-corporation-for-its-migraine-relief-product-300006588.html

SOURCE PuraMed BioScience, Inc.

Related Links

http://www.puramedbioscience.com